chondroitin-sulfates and Vasculitis

Platelets participate in a variety of responses of the blood to injury. An emerging body of evidence suggests that these cells express an intrinsic capacity to interact with and trigger both classical and alternative pathways of complement. This activity requires cell activation with biochemical agonists and/or shear stress, and is associated with the expression of P-selectin, gC1qR, and chondroitin sulfate. Platelet mediated complement activation measurably increases soluble inflammatory mediators (C3a and C5a). Platelets may also serve as targets of classical complement activation in autoimmune conditions such as antiphospholipid syndromes (APS) and immune thrombocytopenia purpura (ITP). Retrospective correlation with clinical data suggests that enhanced platelet associated complement activation correlates with increased arterial thrombotic events in patients with lupus erythematosus and APS, and evidence of enhanced platelet clearance from the circulation in patients with ITP. Taken together, these data support a role for platelet mediated complement activation in vascular inflammation and thrombosis.

Topics: Animals; Antiphospholipid Syndrome; Blood Platelets; Carrier Proteins; Chondroitin Sulfates; Complement Activation; Complement C3a; Complement C5a; Humans; Inflammation Mediators; Lupus Erythematosus, Systemic; Mitochondrial Proteins; P-Selectin; Purpura, Thrombocytopenic, Idiopathic; Thrombosis; Vasculitis